Shots:
TrueLab has granted Bionyra exclusive worldwide rights, excl. Greater China, to research, develop, manufacture, & commercialize TL-001, an anti-TL1A monoclonal antibody, & TL-003, a TL1A × IL-23p19 bispecific antibody
As per the deal, TrueLab will receive ~$985M in total consideration, incl. an upfront payment as well as development, regulatory, & commercial milestone payments, with tiered…
